Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE:BAX) announced five new injectable pharmaceutical product launches in the U.S., bringing their total launches to 10 in 2024. The new products include: Micafungin for Candida infections, Cyclophosphamide Injection for malignant diseases, Pantoprazole Sodium for GERD treatment, Cefazolin in a new 3g/150mL strength for various infections, and Levetiracetam for seizure treatment.

These ready-to-use formats utilize Baxter's proprietary container technology and are designed to improve operational efficiencies, simplify medication preparation, and enhance patient safety by reducing contamination risks and potential compounding errors.

Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.

Baxter International (NYSE:BAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. GMT. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 19, 2025.

Baxter International (NYSE:BAX) has announced its participation in the Stifel 2024 Healthcare Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Monday, November 18, 2024, at 8:35 a.m. Eastern Time. The presentation will be available via live webcast on www.baxter.com and can be accessed for replay through May 17, 2025.

Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.

Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.

Baxter International (NYSE:BAX) announced its participation in the upcoming UBS Global Healthcare Conference. Chief Financial Officer Joel Grade will deliver a presentation on Wednesday, November 13, 2024, at 1:15 p.m. Pacific Time. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 12, 2025.

Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. Interested participants can pre-register for the call through a provided link to receive call information. The conference call will also be webcast and accessible via Baxter's website at www.baxter.com. Baxter has noted that the call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting without the company's permission.

Baxter International Inc. (NYSE:BAX) has provided an update on the impact of Hurricane Helene on its North Cove facility in Marion, N.C. The facility is currently closed for production due to flooding, and the company is working closely with various government agencies to assess the damage and resume operations. Key points:

1. Baxter is implementing measures to minimize supply disruptions, including managing inventory and using a protective allocation process.
2. The company will leverage its global manufacturing network to mitigate potential supply impacts.
3. The Baxter International Foundation has committed $1.5 million in donations for recovery efforts and is matching employee donations 2:1.
4. Baxter anticipates a negative impact on its financial results due to the disruption and plans to provide an update in its third quarter earnings announcement.